Skip to content
The Policy VaultThe Policy Vault

Iclusig (ponatinib) — Medica

Myeloid/Lymphoid Neoplasms with Eosinophilia

Initial criteria

  • Patient age ≥ 18 years
  • The tumor has an ABL1 rearrangement OR the tumor has an FGFR1 rearrangement

Approval duration

1 year